

# Lead compound generation of DYRK1B inhibitor for NASH treatment

Therasid Bioscience



METABOLIC	Lead
Product Type	Small molecule
Indication	NASH (nonalcoholic steatohepatitis)
Target	Dyrk1B
MoA(Mechanism of Action)	Dyrk1B inhibition → AKT/FOXO1A phosphorylation inhibition → reduced Adipogenesis
Competitiveness	The novel effective therapeutic strategy for NASH and obesity.
Development Stage	Lead
Route of Administration	Oral Administration